Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. Chia SK, et al. Among authors: pritchard ki. Clin Cancer Res. 2012 Aug 15;18(16):4465-72. doi: 10.1158/1078-0432.CCR-12-0286. Epub 2012 Jun 18. Clin Cancer Res. 2012. PMID: 22711706 Free PMC article.
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. Cheang MC, et al. Among authors: pritchard ki. Clin Cancer Res. 2012 Apr 15;18(8):2402-12. doi: 10.1158/1078-0432.CCR-11-2956. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351696 Free PMC article. Clinical Trial.
Defining breast cancer intrinsic subtypes by quantitative receptor expression.
Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA. Cheang MC, et al. Among authors: pritchard ki. Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372. Epub 2015 Apr 23. Oncologist. 2015. PMID: 25908555 Free PMC article.
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N; National Cancer Institute of Canada Clinical Trials Group. Levine MN, et al. Among authors: pritchard ki. J Clin Oncol. 2005 Aug 1;23(22):5166-70. doi: 10.1200/JCO.2005.09.423. J Clin Oncol. 2005. PMID: 16051958 Clinical Trial.
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI; National Cancer Institute of Canada Clinical Trials Group. Parulekar WR, et al. Among authors: pritchard ki. J Clin Oncol. 2005 Sep 1;23(25):6002-8. doi: 10.1200/JCO.2005.07.096. J Clin Oncol. 2005. PMID: 16135468
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Ingle JN, et al. Among authors: pritchard ki. Breast Cancer Res Treat. 2006 Oct;99(3):295-300. doi: 10.1007/s10549-006-9207-y. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541302 Clinical Trial.
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN; National Cancer Institute of Canada Clinical Trials Group. Pritchard KI, et al. N Engl J Med. 2006 May 18;354(20):2103-11. doi: 10.1056/NEJMoa054504. N Engl J Med. 2006. PMID: 16707747 Free article. Clinical Trial.
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. Perez EA, et al. Among authors: pritchard ki. J Clin Oncol. 2006 Aug 1;24(22):3629-35. doi: 10.1200/JCO.2005.05.4882. Epub 2006 Jul 5. J Clin Oncol. 2006. PMID: 16822845 Clinical Trial.
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17. Goss PE, et al. Among authors: pritchard ki. J Clin Oncol. 2007 May 20;25(15):2006-11. doi: 10.1200/JCO.2006.09.4482. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452676 Clinical Trial.
344 results